To evaluate the breadth of antitumor activity of RMC-6236 in RAS-mutant human cancers, we conducted a mouse clinical trial (MCT; ref. 29) across a series of xenograft models with KRAS hotspot mutations, which represented key RAS-driven cancer indications. The gene discussed is KRAS; the disease is cancer.